Christopher J. Schultz, MD

Christopher J. Schultz, MD, FACR, FASTRO

Chair and Bernard & Miriam Peck Family Professor of Radiation Oncology

Locations

Radiation Oncology

Contact Information

(414) 805-4472

Education

1985, Medical College of Wisconsin, MD

Biography

Training

Residency Radiation Oncology, University of Wisconsin Hospitals and Clinics, Madison, WI (1989-1990)

Residency Radiation Oncology, Presbyterian Hospital, New York, NY (1986-1988)

Internship Children's Mercy Hospital, Kansas City, MO (1985-1986)

Certifications

Recertification, Radiation Oncology, American Board of Radiology (2000)

Board Certification, Radiation Oncology, American Board of Radiology (1990)

Patient Care Emphases

Head and neck cancer
Hodgkin's Disease
Low dose rate irradiation
Gamma Knife stereotactic radiosurgery
Lymphoma
Brain tumors

View Provider Profile

4D-MRI driven MR-guided online adaptive radiotherapy for abdominal stereotactic body radiation therapy on a high field MR-Linac: Implementation and initial clinical experience.

(Paulson ES, Ahunbay E, Chen X, Mickevicius NJ, Chen GP, Schultz C, Erickson B, Straza M, Hall WA, Li XA.) Clin Transl Radiat Oncol. 2020 Jul;23:72-79 PMID: 32490218 PMCID: PMC7256110 06/04/2020
Lymph node yield from neck dissection in HPV-associated oropharyngeal cancer.

(Zenga J, Stadler M, Massey B, Campbell B, Shukla M, Awan M, Schultz CJ, Wong S, Jackson RS, Pipkorn P.) Laryngoscope. 2020 Mar;130(3):666-671 PMID: 31206708 SCOPUS ID: 2-s2.0-85067854046 06/18/2019
4D-MRI driven MR-guided online adaptive radiotherapy for abdominal stereotactic body radiation therapy on a high field MR-Linac: Implementation and initial clinical experience

(Paulson ES, Ahunbay E, Chen X, Mickevicius NJ, Chen GP, Schultz C, Erickson B, Straza M, Hall WA, Li XA.) Clinical and Translational Radiation Oncology. July 2020;23:72-79 SCOPUS ID: 2-s2.0-85084968086 07/01/2020
Intermediate-grade carcinoma of the parotid and the impact of adjuvant radiation.

(North L, Stadler M, Massey B, Campbell B, Shukla M, Awan M, Schultz CJ, Shreenivas A, Wong S, Graboyes E, Pipkorn P, Zenga J.) Am J Otolaryngol. 2019 Nov - Dec;40(6):102282 PMID: 31519432 SCOPUS ID: 2-s2.0-85071985153 09/15/2019
The transformation of radiation oncology using real-time magnetic resonance guidance: A review.

(Hall WA, Paulson ES, van der Heide UA, Fuller CD, Raaymakers BW, Lagendijk JJW, Li XA, Jaffray DA, Dawson LA, Erickson B, Verheij M, Harrington KJ, Sahgal A, Lee P, Parikh PJ, Bassetti MF, Robinson CG, Minsky BD, Choudhury A, Tersteeg RJHA, Schultz CJ, MR Linac Atlantic Consortium and the ViewRay C2T2 Research Consortium.) Eur J Cancer. 2019 11;122:42-52 PMID: 31614288 SCOPUS ID: 2-s2.0-85073099937 10/16/2019
Lymph node yield, depth of invasion, and survival in node-negative oral cavity cancer.

(Zenga J, Divi V, Stadler M, Massey B, Campbell B, Shukla M, Awan M, Schultz CJ, Shreenivas A, Wong S, Jackson RS, Pipkorn P.) Oral Oncol. 2019 11;98:125-131 PMID: 31586894 SCOPUS ID: 2-s2.0-85072773115 10/07/2019
Salvage of Recurrence after Surgery and Adjuvant Therapy: A Multi-institutional Study.

(Zenga J, Graboyes E, Janz T, Drake V, Rettig E, Desai S, Nickel C, Shabani S, Padhya T, Scarpinato M, Stadler M, Massey B, Campbell B, Shukla M, Awan M, Schultz CJ, Wong S, Jackson RS, Pipkorn P.) Otolaryngol Head Neck Surg. 2019 07;161(1):74-81 PMID: 30753110 SCOPUS ID: 2-s2.0-85061834834 02/13/2019
Serial T2-Weighted Magnetic Resonance Images Acquired on a 1.5 Tesla Magnetic Resonance Linear Accelerator Reveal Radiomic Feature Variation in Organs at Risk: An Exploratory Analysis of Novel Metrics of Tissue Response in Prostate Cancer.

(Lorenz JW, Schott D, Rein L, Mostafaei F, Noid G, Lawton C, Bedi M, Li XA, Schultz CJ, Paulson E, Hall WA.) Cureus. 2019 Apr 20;11(4):e4510 PMID: 31259119 PMCID: PMC6590865 07/02/2019
Reassessing the Role of Radiation Therapy for the Treatment of Lymphoma: Historical Perspective and Opportunities in the Era of Image-Guided and Adaptive Radiation Therapy.

(Schultz CJ.) J Oncol Pract. 2019 04;15(4):175-176 PMID: 30970226 SCOPUS ID: 2-s2.0-85064721617 04/11/2019
Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420.

(Lieberman FS, Wang M, Robins HI, Tsien CI, Curran WJ Jr, Werner-Wasik M, Smith RP, Schultz C, Hartford AC, Zhang P, Mehta MP.) Int J Radiat Oncol Biol Phys. 2019 03 15;103(4):878-886 PMID: 30496882 PMCID: PMC7034757 SCOPUS ID: 2-s2.0-85061550338 11/30/2018
The association between BMI and BSA-temozolomideinduced myelosuppression toxicities: A correlative analysis of NRG oncology RTOG 0525

(Robins HI, Eickhoff J, Gilbert MR, Armstrong TS, Shi W, De Groot JF, Schultz CJ, Hunter GK, Valeinis E, Roach M, Youssef EF, Souhami L, Howard SP, Lieberman FS, Herman JG, Zhang P, Mehta MP.) Neuro-Oncology Practice. 1 December 2019;6(6):473-478 SCOPUS ID: 2-s2.0-85079125614 12/01/2019
Intermediate-grade carcinoma of the parotid and the impact of adjuvant radiation

(North L, Stadler M, Massey B, Campbell B, Shukla M, Awan M, Schultz CJ, Shreenivas A, Wong S, Graboyes E, Pipkorn P, Zenga J.) American Journal of Otolaryngology - Head and Neck Medicine and Surgery. 2019 SCOPUS ID: 2-s2.0-85071985153 01/01/2019